Kane Biotech Inc.

Kane Biotech Inc.

January 31, 2013 08:00 ET

This Smile Brought To You By Science-StrixNB™

Kane Biotech Introduces Revolutionary New Pet Oral Care Product

WINNIPEG, MANITOBA--(Marketwire - Jan. 31, 2013) - Kane Biotech Inc. (TSX VENTURE:KNE), will launch its marketing field test for StrixNB, its revolutionary new pet oral care product, in Manitoba on February 1, 2013 in conjunction with Pet Dental Health Month. Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. Manitoba pet owners will be the first in Canada to have access to this easy-to-use companion animal oral care product that has the potential to change the way we care for our pets' teeth.

StrixNB is a new, safe and effective drinking water additive scientifically formulated to help maintain and promote good dental and oral hygiene in pets. It is unique because it works against bacteria associated with dental disease by altering the mouth's environment. It breaks through dental biofilm - a highly structured, matrix-embedded microbial population - making bacteria accessible for eradication by a microbial agent.

When you take care of your pet's dental health, you help keep your pet - and you - worry-free. Dental diseases cause discomfort and can lead to diminished appetite and weight loss. Worse still: some dental diseases, such as periodontal disease, can create bacteria able to travel into your pet's bloodstream, affecting the lungs, heart, kidneys, liver and nervous system.

StrixNB is made using a unique formulation of food grade ingredients and has received a notification number NN.1Q11 from the Interim Notification Program of Health Canada for Low Risk Veterinary Health Products. It is safe for everyday consumption and works for all breeds and sizes of dogs.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with, and are involved in approximately 80 per cent of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information